502 related articles for article (PubMed ID: 29641322)
61. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.
Singh H; Moyes JS; Huls MH; Cooper LJ
Cancer Gene Ther; 2015 Mar; 22(2):95-100. PubMed ID: 25591810
[TBL] [Abstract][Full Text] [Related]
62. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.
Singh H; Srour SA; Milton DR; McCarty J; Dai C; Gaballa MR; Ammari M; Olivares S; Huls H; De Groot E; Marin D; Petropoulos D; Olson AL; Anderlini P; Im JS; Khouri I; Hosing CM; Rezvani K; Champlin RE; Shpall EJ; Cooper LJN; Kebriaei P
Front Immunol; 2022; 13():1032397. PubMed ID: 36439104
[TBL] [Abstract][Full Text] [Related]
63. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement.
Suematsu M; Yagyu S; Yoshida H; Osone S; Nakazawa Y; Sugita K; Imamura T; Iehara T
Cancer Immunol Immunother; 2023 Apr; 72(4):957-968. PubMed ID: 36214866
[TBL] [Abstract][Full Text] [Related]
64. Developers seek to finetune toxicity of T-cell therapies.
Morrison C
Nat Biotechnol; 2014 Dec; 32(12):1171-2. PubMed ID: 25489817
[No Abstract] [Full Text] [Related]
65. Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.
Sawaisorn P; Atjanasuppat K; Uaesoontrachoon K; Rattananon P; Treesuppharat W; Hongeng S; Anurathapan U
PLoS One; 2023; 18(2):e0281735. PubMed ID: 36780428
[TBL] [Abstract][Full Text] [Related]
66. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
67. Efficient Non-Viral T-Cell Engineering by Sleeping Beauty Minicircles Diminishing DNA Toxicity and miRNAs Silencing the Endogenous T-Cell Receptors.
Clauss J; Obenaus M; Miskey C; Ivics Z; Izsvák Z; Uckert W; Bunse M
Hum Gene Ther; 2018 May; 29(5):569-584. PubMed ID: 29562762
[TBL] [Abstract][Full Text] [Related]
68. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.
Rossig C; Pule M; Altvater B; Saiagh S; Wright G; Ghorashian S; Clifton-Hadley L; Champion K; Sattar Z; Popova B; Hackshaw A; Smith P; Roberts T; Biagi E; Dreno B; Rousseau R; Kailayangiri S; Ahlmann M; Hough R; Kremens B; Sauer MG; Veys P; Goulden N; Cummins M; Amrolia PJ
Leukemia; 2017 May; 31(5):1087-1095. PubMed ID: 28126984
[TBL] [Abstract][Full Text] [Related]
69. CAR therapy: the CD19 paradigm.
Sadelain M
J Clin Invest; 2015 Sep; 125(9):3392-400. PubMed ID: 26325036
[TBL] [Abstract][Full Text] [Related]
70. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Braendstrup P; Levine BL; Ruella M
Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
[TBL] [Abstract][Full Text] [Related]
71. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
72. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
[TBL] [Abstract][Full Text] [Related]
73. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system.
Khaniya A; Rad SMAH; Halpin J; Tawinwung S; McLellan A; Suppipat K; Hirankarn N
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677881
[TBL] [Abstract][Full Text] [Related]
74. Chimeric antigen receptor T-cell therapy for ALL.
Maude SL; Shpall EJ; Grupp SA
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911
[TBL] [Abstract][Full Text] [Related]
75. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
[TBL] [Abstract][Full Text] [Related]
76. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia.
Zebley CC; Brown C; Mi T; Fan Y; Alli S; Boi S; Galletti G; Lugli E; Langfitt D; Metais JY; Lockey T; Meagher M; Triplett B; Talleur AC; Gottschalk S; Youngblood B
Cell Rep; 2021 Nov; 37(9):110079. PubMed ID: 34852226
[TBL] [Abstract][Full Text] [Related]
77. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
78. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
Aldoss I; Forman SJ
Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
[TBL] [Abstract][Full Text] [Related]
79. A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia.
Wang J; Zhang X; Zhou Z; Liu Y; Yu L; Jia L; Yang J; Li J; Yu H; Li W; Liu G; Rui W; Zheng H; Zhao X; Lin X; Lu P
Am J Hematol; 2022 Aug; 97(8):992-1004. PubMed ID: 35491511
[TBL] [Abstract][Full Text] [Related]
80. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
